Stem cell transplant add-on that removes some immune cells
Part of Blood & lymphatic clinical trials.
This trial tests a lab-made cell treatment added around an allogeneic stem cell transplant (donor transplant). It tries to improve transplant safety and outcomes by removing certain immune cells from the donor stem cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You need a donor (allogeneic) stem cell transplant
- You must be from birth to age 70
- You (or a legal caregiver) can understand the study and sign consent
- You must be in one of the study groups based on whether you’re getting conditioning (intensive chemo) or additional “CD34+ topoff” cells
- For the “CD34+ topoff” groups, you must have at least one issue: mixed donor cells, weak marrow/blood counts, or relapsed/persistent disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of stem cell transplant that removes certain immune cells (alpha-beta T cells and CD19 B cells) from the donor cells. This may help prevent graft-versus-host disease and other complications in patients with blood cancers who do not have a matched sibling donor.
This trial gives patients access to a special machine that cleans stem cells before they are transplanted, which may reduce the risk of graft-versus-host disease. It is for patients getting certain types of stem cell transplants or having poor graft function after a transplant.
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
This trial tests whether adding back certain immune cells after a stem cell transplant can help prevent serious viral or fungal infections. It's for children and young adults up to age 25 who need a transplant for a blood cancer or other curable disease.
This trial tests a stem cell transplant from a matched sibling donor, followed by extra immune cells to help prevent relapse in people with high-risk acute myeloid leukemia (AML) who are in remission. It aims to improve outcomes by boosting the immune system's ability to fight any remaining leukemia cells.
This trial tests a risk-adapted conditioning regimen (chemotherapy and/or radiation given before transplant) for people with certain blood cancers or bone marrow disorders who need a stem cell transplant from a donor. The goal is to tailor the conditioning strength to each patient’s risk, which may help improve outcomes and reduce side effects.
Hear when a new Stem Cell Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.